Want to see JP:4594 full AI Analyst Report?
BrightPath Biotherapeutics Co.Ltd. (4594) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bp2202 | Relapsed/Refractory Multiple Myeloma (Rrmm) | Phase I | Not Yet Recruiting | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma | Jun 19, 2026 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bp2202 | Phase I | Relapsed/Refractory Multiple Myeloma (Rrmm) | Not Yet Recruiting | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma | Jun 19, 2026 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does BrightPath Biotherapeutics Co.Ltd. (JP:4594) have in its pipeline
BrightPath Biotherapeutics Co.Ltd. JP:4594 is currently developing the following drugs: Bp2202. These drug candidates are in various stages of clinical development as the company works toward FDA approval.